Thymosin β4 promotes autophagy and repair via HIF-1α stabilization in chronic granulomatous disease
Life Science Alliance, ISSN: 2575-1077, Vol: 2, Issue: 6
2019
- 15Citations
- 11Usage
- 13Captures
- 14Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations15
- Citation Indexes15
- 15
- CrossRef13
- Usage11
- Abstract Views11
- Captures13
- Readers13
- 13
- Mentions14
- News Mentions14
- News14
Most Recent News
November 14, 2019: RegeneRx's Tβ4 Promotes Autophagy and Repair in Chronic Granulomatous Disease Model
ROCKVILLE, Md., Nov. 14, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or the "Company"), a clinical-stage drug development company focused on tissue protection,
Article Description
Chronic granulomatous disease (CGD) is a genetic disorder of the NADPH oxidase characterized by increased susceptibility to infections and hyperinflammation associated with defective autophagy and increased inflammasome activation. Herein, we demonstrate that thymosin β4 (Tβ4), a g-actin sequestering peptide with multiple and diverse intracellular and extracellular activities affecting inflammation, wound healing, fibrosis, and tissue regeneration, promoted in human and murine cells noncanonical autophagy, a form of autophagy associated with phagocytosis and limited inflammation via the death-associated protein kinase 1. We further show that the hypoxia inducible factor-1 (HIF-1)α was underexpressed in CGD but normalized by Tβ4 to promote autophagy and up-regulate genes involved in mucosal barrier protection. Accordingly, inflammation and granuloma formation were impaired and survival increased in CGD mice with colitis or aspergillosis upon Tβ4 treatment or HIF-1α stabilization. Thus, the promotion of endogenous pathways of inflammation resolution through HIF-1α stabilization is druggable in CGD by Tβ4.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85074951850&origin=inward; http://dx.doi.org/10.26508/lsa.201900432; http://www.ncbi.nlm.nih.gov/pubmed/31719116; https://www.life-science-alliance.org/lookup/doi/10.26508/lsa.201900432; https://hsrc.himmelfarb.gwu.edu/smhs_biochem_facpubs/378; https://hsrc.himmelfarb.gwu.edu/cgi/viewcontent.cgi?article=1380&context=smhs_biochem_facpubs; https://dx.doi.org/10.26508/lsa.201900432; https://www.life-science-alliance.org/content/2/6/e201900432
Life Science Alliance, LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know